CompletedNCT00139919
Shorter bifeprunox dose titration in schizophrenia or bipolarity
About this title
Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
Read the official source — NCT00139919Medication studyAges 18–55United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- OrangeSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJanuary 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Solvay Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00139919
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study of the Safety and Tolerability of Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Either Schizophrenia or Bipolar Disorder With an Optional Open-Label 26-Week Extension Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Orange
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Solvay Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Bifeprunox.
Who was this study for?
Listed age limits: 18 years to 55 years.
